• Fri news: New Novo obesity prospect linked to psychiatric side effects. Summit beats Keytruda in NSCLC. DermaSensor skin cancer detection device. Astellas digital health product. Sanofi MS data. See more on our front page

Gilead’s Kite pens 10-target CAR-T tech deal with MaxCyte

cafead

Administrator
Staff member
  • cafead   Mar 02, 2019 at 12:52: PM
via Gilead’s Kite Pharma has expanded its CAR-T agreement with MaxCyte. The revised deal gives Kite the chance to apply MaxCyte’s transfection technology to up to 10 targets.

article source
 

<